Related Experiment Videos
Presence of anticardiolipin antibodies discriminates between Wegener's granulomatosis and microscopic polyarteritis
O Hergesell1, R Egbring, K Andrassy
1Departments of Medicine, University of Heidelberg, FRG.
Abstract:
ANCA-tests are not always useful in evaluation of disease activity of patients with Wegener's granulomatosis (WG) and microscopic polyarteritis(MP). If ANCA-tests are failing in patients with Wegener's granulomatosis or microscopic polyarteritis, markers of activated coagulation are helpful in evaluation of disease activity. The measurement of anticardiolipin antibodies(ACA) may allow to discriminate between MP and WG, since ACA are only significantly elevated in patients with MP. Anticardiolipin antibodies (ACA) are acquired autoantibodies that are found in patients with a wide spectrum of clinical conditions, mainly systemic lupus erythematosus and related disorders. They are associated with increased thrombotic tendency. We investigated in patients with ANCA-positive vasculitis whether membrane phospholipids exposed in injured endothelial cells might stimulate the formation of ACA, thus contributing to the vascular thrombotic occlusion besides the activation of coagulation.
Insights
Antineutrophil cytoplasmic antibody (ANCA) tests may not always reflect disease activity in Wegener's granulomatosis (WG) or microscopic polyarteritis (MP). Anticardiolipin antibodies (ACA) may help differentiate MP from WG and indicate thrombotic risk.
Area of Science:
- Rheumatology
- Immunology
- Vascular Biology
Background:
- Antineutrophil cytoplasmic antibody (ANCA) tests are crucial for diagnosing ANCA-associated vasculitis but can be unreliable for monitoring disease activity in Wegener's granulomatosis (WG) and microscopic polyarteritis (MP).
- Activated coagulation markers may offer an alternative for assessing disease activity when ANCA tests are inconclusive.
- Anticardiolipin antibodies (ACA) are associated with thrombotic events and are found in various autoimmune conditions.
Purpose of the Study:
- To evaluate the utility of ANCA tests in assessing disease activity in WG and MP.
- To explore the role of activated coagulation markers in monitoring disease activity when ANCA tests are negative or uninformative.
- To investigate whether anticardiolipin antibodies (ACA) can differentiate between MP and WG and if they are linked to thrombotic complications in ANCA-positive vasculitis.
Main Methods:
- Retrospective analysis of ANCA test results and disease activity markers in patients with WG and MP.
- Measurement of anticardiolipin antibodies (ACA) in patients with ANCA-positive vasculitis.
- Assessment of coagulation activation markers.
Main Results:
- ANCA tests are not consistently reliable for evaluating disease activity in WG and MP.
- Activated coagulation markers show promise in assessing disease activity when ANCA tests are inconclusive.
- Significantly elevated ACA levels were observed in patients with MP, suggesting potential for differentiating between MP and WG.
- The study explored the hypothesis that exposed membrane phospholipids in injured endothelial cells might stimulate ACA formation, contributing to thrombosis.
Conclusions:
- Activated coagulation markers are valuable for monitoring disease activity in WG and MP, especially when ANCA tests are unreliable.
- Anticardiolipin antibodies (ACA) may serve as a biomarker to distinguish between MP and WG.
- Further research is warranted to elucidate the role of ACA in the pathogenesis of thrombotic events in ANCA-positive vasculitis.